We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
+5.98%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$202M
AUM Growth
+$26.7M
(+15%)
Cap. Flow
+$32.8M
Cap. Flow
% of AUM
16.19%
Top 10 Holdings %
Top 10 Hldgs %
64.02%
Holding
54
New
24
Increased
5
Reduced
9
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$11.5M |
| 2 |
RXDX
Ignyta, Inc.
RXDX
|
+$6.33M |
| 3 |
AVDL
Avadel Pharmaceuticals
AVDL
|
+$5.74M |
| 4 |
AET
Aetna Inc
AET
|
+$4.57M |
| 5 |
Amgen
AMGN
|
+$4.54M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$8.34M |
| 2 |
United Therapeutics
UTHR
|
+$5.98M |
| 3 |
PFNX
Pfenex Inc.
PFNX
|
+$5.15M |
| 4 |
UnitedHealth
UNH
|
+$3.13M |
| 5 |
GTS
Triple-S Management Corporation
GTS
|
+$2.23M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 58.72% |
| 2 | Miscellaneous | 38.77% |
| 3 | Financials | 2.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
Gilead Sciences
GILD
$181B
| $58.5M | 28.92% |
+500,000
| New | +$54.6M |
|
|
QTNT
2
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $16.2M | 7.99% |
27,325
-766
| -3% | -$472K |
|
|
3
GSK
GSK
$102B
| $10.6M | 5.25% |
+204,000
| New | +$11.5M |
|
|
RXDX
4
DELISTED
Ignyta, Inc.
RXDX
| $7.89M | 3.9% |
+522,756
| New | +$6.33M |
|
|
AVDL
5
DELISTED
Avadel Pharmaceuticals
AVDL
| $6.78M | 3.35% |
+320,000
| New | +$5.74M |
|
|
PFNX
6
DELISTED
Pfenex Inc.
PFNX
| $6.71M | 3.32% |
346,128
-307,265
| -47% | -$5.15M |
|
7
Johnson & Johnson
JNJ
$646B
| $6.25M | 3.09% |
64,177
+19,177
| +43% | +$1.92M |
|
|
PETX
8
DELISTED
Aratana Therapeutics, Inc.
PETX
| $6.12M | 3.02% |
404,738
+226,188
| +127% | +$3.27M |
|
9
Cardinal Health
CAH
$54.6B
| $5.29M | 2.62% |
63,278
+5,278
| +9% | +$466K |
|
10
Addus HomeCare
ADUS
$2.16B
| $5.18M | 2.56% |
186,055
-3,411
| -2% | -$93.4K |
|
|
DMK
11
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
| $5.13M | 2.54% |
17,461
+604
| +4% | +$182K |
|
|
AET
12
DELISTED
Aetna Inc
AET
| $5.1M | 2.52% |
+40,000
| New | +$4.57M |
|
13
PUT
Pfizer
PFE
$159B
| $5.03M | 2.49% |
+158,100
| New | +$5.15M |
|
|
14
Amgen
AMGN
$234B
| $4.35M | 2.15% |
+28,349
| New | +$4.54M |
|
|
HNGR
15
DELISTED
Hanger Inc.
HNGR
| $4.12M | 2.04% |
+175,859
| New | +$4.1M |
|
16
Medtronic
MDT
$117B
| $4.11M | 2.03% |
+55,400
| New | +$4.23M |
|
17
Ascendis Pharma A/S
ASND
$16.3B
| $3.58M | 1.77% |
+202,525
| New | +$3.54M |
|
18
Alnylam Pharmaceuticals
ALNY
$31.7B
| $3.24M | 1.6% |
+27,000
| New | +$3.23M |
|
19
Stryker
SYK
$127B
| $3.18M | 1.57% |
+33,300
| New | +$3.16M |
|
|
20
PUT
Johnson & Johnson
JNJ
$646B
| $2.92M | 1.44% |
30,000
-20,000
| -40% | -$2M |
|
21
Cigna
CI
$73.7B
| $2.86M | 1.41% |
+17,640
| New | +$2.44M |
|
22
Ironwood Pharmaceuticals
IRWD
$682M
| $2.86M | 1.41% |
+282,978
| New | +$3.29M |
|
|
IMMU
23
PUT
DELISTED
Immunomedics Inc
IMMU
| $2.7M | 1.33% |
+664,900
| New | +$2.72M |
|
24
PUT
Eli Lilly
LLY
$1.05T
| $2.5M | 1.24% |
30,000
-70,000
| -70% | -$5.33M |
|
25
PUT
Abbott
ABT
$195B
| $2.45M | 1.21% |
+50,000
| New | +$2.4M |
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q2 2015 Portfolio in Review
As of Q2 2015, Sio Capital Management held 54 positions worth $202M, up 15% from $176M the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Sio Capital Management deployed $32.8M of net new capital in Q2 2015, opening 24 new positions and adding to 5 existing holdings. Its largest new stake was GSK: 204,000 shares worth $10.6M.
By sector, the portfolio is most concentrated in Healthcare at 59% of assets, up from 50% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Pfenex Inc., an estimated $5.15M trimmed.
- Sio Capital Management's largest Q2 2015 buy was GSK: 204,000 shares worth $10.6M.
- Sio Capital Management added most to Aratana Therapeutics, Inc. in Q2 2015, an estimated $3.27M increase.
- Sio Capital Management's biggest Q2 2015 reduction was Pfenex Inc., cutting an estimated $5.15M.
- Sio Capital Management fully exited Merck in Q2 2015, selling an estimated $8.34M.
- Sio Capital Management's ten largest holdings make up 64% of its $202M portfolio in Q2 2015.
- Sio Capital Management opened 24 new positions and closed 15 in Q2 2015.
- Sio Capital Management's portfolio value rose 15% quarter-over-quarter to $202M.
Based on Sio Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.